Paper40596117
Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA.
Virga A and 18 others. Sci Rep, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA. Papers, record 40596117. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40596117
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Whole Genome Sequencing | Major topic |
| Mutation | Major topic |
| Prostatic Neoplasms, Castration-Resistant | Major topic |
| Circulating Tumor DNA | Major topic |
| Prostatic Neoplasms | Major topic |
| DNA Repair | Major topic |
| DNA, Neoplasm | Major topic |
| Recombinational DNA Repair | Major topic |
| Humans | |
| Male | |
| Aged | |
| Middle Aged | |
| DNA Mutational Analysis | |
| Liquid Biopsy | |
| Aged, 80 and over |
Source PubMed
References66
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34753780 | The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/34753780 | PubMed |
| 2 | 31068988 | Epidemiology of Prostate Cancer. | World J Oncol | 2019 | https://conductscience.org/library/papers/31068988 | PubMed |
| 3 | 35020204 | Cancer statistics, 2022. | CA Cancer J Clin | 2022 | https://conductscience.org/library/papers/35020204 | PubMed |
| 4 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 5 | 16234520 | Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/16234520 | PubMed |
| 6 | 33487630 | Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. | Exp Mol Med | 2021 | https://conductscience.org/library/papers/33487630 | PubMed |
| 7 | 32220891 | Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32220891 | PubMed |
| 8 | 27433846 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27433846 | PubMed |
| 9 | 30553611 | Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. | Eur Urol | 2019 | https://conductscience.org/library/papers/30553611 | PubMed |
| 10 | 32955174 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32955174 | PubMed |
| 11 | 40107449 | Effects of exercise on inflammation, circulating tumor cells, and circulating tumor DNA in colorectal cancer. | J Sport Health Sci | 2025 | https://conductscience.org/library/papers/40107449 | PubMed |
| 12 | 36059000 | Accumulation of copy number alterations and clinical progression across advanced prostate cancer. | Genome Med | 2022 | https://conductscience.org/library/papers/36059000 | PubMed |
| 13 | 29109393 | Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. | Nat Commun | 2017 | https://conductscience.org/library/papers/29109393 | PubMed |
| 14 | 35091440 | Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35091440 | PubMed |
| 15 | 32461654 | The mutational constraint spectrum quantified from variation in 141,456 humans. | Nature | 2020 | https://conductscience.org/library/papers/32461654 | PubMed |
| 16 | 38384439 | Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study. | Eur Urol Open Sci | 2024 | https://conductscience.org/library/papers/38384439 | PubMed |
| 17 | 28446639 | Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer. | Mol Cancer Ther | 2017 | https://conductscience.org/library/papers/28446639 | PubMed |
| 18 | 37538150 | Cell-free DNA in the management of prostate cancer: Current status and future prospective. | Asian J Urol | 2023 | https://conductscience.org/library/papers/37538150 | PubMed |
| 19 | 38418825 | Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. | Nat Commun | 2024 | https://conductscience.org/library/papers/38418825 | PubMed |
| 20 | 38201592 | Clinical Biofluid Assays for Prostate Cancer. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38201592 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42489928 | Towards implementation of precision medicine biomarkers in early detection and prognostication of prostate cancer. | Cancer Metastasis Rev | 2026 | https://conductscience.org/library/papers/42489928 | PubMed |
| 41347816 | Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review). | Int J Oncol | 2026 | https://conductscience.org/library/papers/41347816 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40596117
GET https://conductscience.org/api/papers/v1/40596117/references?page=2